Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
NCT ID: NCT01243177
Last Updated: 2021-02-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
888 participants
INTERVENTIONAL
2011-04-30
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
NCT01465997
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
NCT01921205
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
NCT01964560
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
NCT02408549
A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.
NCT01969851
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lacosamide
Lacosamide
Lacosamide:
* Strengths: 50 mg / 100 mg
* Form: tablets
* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose
* Duration: up to 118 weeks
Carbamazepine-Controlled Release (CBZ-CR)
Carbamazepine-Controlled Release
Carbamazepine-CR:
* Strengths: 200 mg
* Form: tablets
* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose
* Duration: up to 118 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lacosamide
Lacosamide:
* Strengths: 50 mg / 100 mg
* Form: tablets
* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose
* Duration: up to 118 weeks
Carbamazepine-Controlled Release
Carbamazepine-CR:
* Strengths: 200 mg
* Form: tablets
* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose
* Duration: up to 118 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is 16 years and older (female; male). Minors will be included in countries only if legally permitted
* Subject has newly or recently diagnosed Epilepsy experiencing partial onset seizures (POS) or generalized tonic-clonic seizures with at least 2 unprovoked seizures separated by 48 hours in the 12 months preceding Visit 1 out of which at least 1 seizure occured 3 months preceding Visit 1
* Subject has had an Electroencephalogram (EEG) and a brain Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) exam of the brain within the past 12 months. If the EEG and brain CT scan or MRI exam were not performed prior to Visit 1, they need to be completed and results must be available prior to randomization at Visit 2
Exclusion Criteria
* Subject has a history or presence of seizures occurring only in clustered patterns, defined as repeated seizures occurring over a short period of time (ie, \< 20 minutes) with or without function regained between 2 ictal events
* Subject has a history, clinical, or Electroencephalogram (EEG) finding suggestive of Idiopathic Generalized Epilepsy (IGE) at randomization
* Subject has current or previous diagnosis of pseudoseizures, conversion disorders, or other nonepileptic ictal events that could be confused with seizures based on expert opinion and/or EEG evidence
* Subject has any medical or psychiatric condition
* Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening
* Subject has received treatment with Phenobarbital or Primidone within 28 days prior to Visit 1
* Subject is taking Benzodiazepines for a nonepilepsy indication
* Subject has been treated for Epilepsy with any Antiepileptic Drug (AED) (including Benzodiazepines) in the last 6 months before Visit. However, acute and subacute seizure treatment is accepted with a maximum of 2 weeks duration and if treatment was stopped at least 3 days prior to randomization
* Prior use of Felbamate or Vigabatrin is not allowed
* Benzodiazepines as rescue therapy for Epilepsy may have been used as needed in this time period, but not more frequently than once per week
* Subject has a medical condition that could reasonably be expected to interfere with drug absorption, distribution, metabolism, or excretion, has a history of alcohol or drug abuse within the previous 2 years
* Asian ancestry and tests positive for HLA-B\*1502 allele
* Asian ancestry and tests positive for HLA-A\*3101 allele
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eden Sarl
INDUSTRY
UCB BIOSCIENCES GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
786
Alabaster, Alabama, United States
799
Huntsville, Alabama, United States
780
Phoenix, Arizona, United States
777
Little Rock, Arkansas, United States
795
Ocala, Florida, United States
789
Panama City, Florida, United States
776
Port Charlotte, Florida, United States
779
Manhattan, Kansas, United States
874
Charlotte, North Carolina, United States
876
Hickory, North Carolina, United States
873
Raleigh, North Carolina, United States
794
Oklahoma City, Oklahoma, United States
881
Mansfield, Texas, United States
790
Madison, Wisconsin, United States
798
Casper, Wyoming, United States
106
East Gosford, New South Wales, Australia
109
Randwick, New South Wales, Australia
102
Westmead, New South Wales, Australia
103
Herston, Queensland, Australia
100
Woodville, South Australia, Australia
101
Fitzroy, Victoria, Australia
108
Heidelberg, Victoria, Australia
104
Chatswood, , Australia
105
Clayton, , Australia
127
Bruges, , Belgium
134
Bruges, , Belgium
128
Hasselt, , Belgium
126
Leuven, , Belgium
805
Blagoevgrad, , Bulgaria
807
Panagyurishte, , Bulgaria
803
Pleven, , Bulgaria
810
Rousse, , Bulgaria
806
Sofia, , Bulgaria
808
Sofia, , Bulgaria
811
Sofia, , Bulgaria
809
Veliko Tarnovo, , Bulgaria
153
St. John's, Newfoundland and Labrador, Canada
152
Greenfield Park, Quebec, Canada
155
Calgary, , Canada
158
Halifax Nova Scotia, , Canada
156
Hamilton, , Canada
159
Veilleux, , Canada
185
Brno, , Czechia
190
Ostrava - Vitkovice, , Czechia
184
Prague, , Czechia
189
Prague, , Czechia
180
Zlín, , Czechia
205
Helsinki, , Finland
207
Kuopio, , Finland
236
Nancy, , France
233
Paris, , France
231
Strasbourg, , France
235
Toulouse, , France
263
Altenburg, , Germany
258
Aschaffenburg, , Germany
265
Bad Neustadt an der Saale, , Germany
257
Berlin, , Germany
262
Berlin, , Germany
270
Berlin, , Germany
271
Cologne, , Germany
260
Göttingen, , Germany
269
Leipzig, , Germany
256
Marburg, , Germany
264
München, , Germany
261
Münster, , Germany
259
Osnabrück, , Germany
496
Alexandroupoli, , Greece
495
Ioannina, , Greece
493
Thessaloniki, , Greece
490
Thessalonikis, , Greece
289
Balassagyarmat, , Hungary
283
Budapest, , Hungary
284
Budapest, , Hungary
286
Debrecen, , Hungary
282
Győr, , Hungary
288
Pécs, , Hungary
285
Szeged, , Hungary
290
Szekszárd, , Hungary
291
Szombathely, , Hungary
310
Bari, , Italy
309
Modena, , Italy
308
Padua, , Italy
314
Prato, , Italy
311
Roma, , Italy
831
Asaka-shi, , Japan
833
Hamamatsu, , Japan
834
Kagoshima, , Japan
844
Kamakura-shi, , Japan
846
Kawasaki-shi, , Japan
829
Kokubunji-shi, , Japan
843
Miyakonojō, , Japan
835
Nagoya, , Japan
830
Nara, , Japan
837
Okayama, , Japan
828
Saitama-shi, , Japan
836
Sapporo, , Japan
847
Sapporo, , Japan
832
Shizuoka, , Japan
751
Riga, , Latvia
727
Alytus, , Lithuania
724
Kaunas, , Lithuania
728
Vilnius, , Lithuania
547
San Luis Potosí City, , Mexico
673
Manila, , Philippines
672
Pasig, , Philippines
676
Quezon City, , Philippines
336
Gdansk, , Poland
334
Katowice, , Poland
340
Katowice, , Poland
342
Lublin, , Poland
341
Poznan, , Poland
338
Szczecin, , Poland
343
Warsaw, , Poland
360
Coimbra, , Portugal
362
Lisbon, , Portugal
365
Lisbon, , Portugal
366
Porto, , Portugal
361
Santa Maria da Feira, , Portugal
576
Bucharest, , Romania
569
Cluj-Napoca, , Romania
578
Craiova, , Romania
570
Iași, , Romania
579
Iași, , Romania
571
Sibiu, , Romania
577
Sibiu, , Romania
572
Târgu Mureş, , Romania
387
Kazan', , Russia
389
Kazan', , Russia
396
Kirov, , Russia
394
Moscow, , Russia
401
Moscow, , Russia
390
Nizhny Novgorod, , Russia
392
Novosibirsk, , Russia
397
Saint Petersburg, , Russia
400
Saint Petersburg, , Russia
386
Smolensk, , Russia
399
Yaroslavl, , Russia
594
Dolný Kubín, , Slovakia
598
Dubnica nad Váhom, , Slovakia
596
Hlohovec, , Slovakia
600
Krompachy, , Slovakia
595
Levoča, , Slovakia
599
Tornaľa, , Slovakia
601
Žilina, , Slovakia
525
Busan, , South Korea
521
Daegu, , South Korea
518
Dajeon, , South Korea
516
Seoul, , South Korea
517
Seoul, , South Korea
519
Seoul, , South Korea
520
Seoul, , South Korea
523
Seoul, , South Korea
524
Seoul, , South Korea
422
Badalona, , Spain
413
Barcelona, , Spain
418
Donostia / San Sebastian, , Spain
416
Madrid, , Spain
425
Madrid, , Spain
426
Madrid, , Spain
421
Murcia (El Palmar), , Spain
419
San Cristóbal de La Laguna, , Spain
414
Santiago de Compostela, , Spain
424
Seville, , Spain
440
Gothenburg, , Sweden
438
Stockholm, , Sweden
442
Umeå, , Sweden
651
Aarau, , Switzerland
654
Biel, , Switzerland
653
Lugano, , Switzerland
647
Sankt Gallen, , Switzerland
699
Bangkok, , Thailand
702
Bangkok, , Thailand
703
Bangkok, , Thailand
698
Khon Kaen, , Thailand
622
Chernihiv, , Ukraine
628
Dnipropetrovsk, , Ukraine
626
Kharkiv, , Ukraine
621
Luhansk, , Ukraine
625
Odesa, , Ukraine
632
Simferopol, , Ukraine
633
Vinnytsa, , Ukraine
466
Birmingham, , United Kingdom
472
Glasgow, , United Kingdom
471
Stoke-on-Trent, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017 Jan;16(1):43-54. doi: 10.1016/S1474-4422(16)30292-7. Epub 2016 Nov 24.
Mintzer S, Dimova S, Zhang Y, Steiniger-Brach B, De Backer M, Chellun D, Roebling R. Effects of lacosamide and carbamazepine on lipids in a randomized trial. Epilepsia. 2020 Dec;61(12):2696-2704. doi: 10.1111/epi.16745. Epub 2020 Nov 17.
Lindauer A, Laveille C, Stockis A. Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy. Clin Pharmacokinet. 2017 Nov;56(11):1403-1413. doi: 10.1007/s40262-017-0530-8.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-019765-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
SP0993
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.